Clinical Trial Search

Primary: Percentage of Patients Achieving a Complete Response (CR), Partial Response (PR), or Stable Disease (SD) on Single Agent CC-5013 at 6 Months — 68.9 percentage of…

Primary: Overall Response Rate (ORR) — 25 Participants

Primary: Number of Patients With Confirmed Objective Status of Complete Response (CR), Complete Clinical Response (CCR), Nodular Partial Response (nPR), or Partial Response (PR)…

Primary: Complete Response (CR) — 8.3 Percentage of participants with CR — p=0.014

Primary: Number of Patients With Dose-Limiting Toxicities Adverse Events (DLTs) — 0; 0; 0; 0 Participants

Primary: Overall Response Rate (ORR) by Independent Review Committee (IRC) — 80 Participants — p=<0.0001

Primary: Number of Participants With Treatment-emergent Adverse Events — 34; 34; 35; 33 Participants

Primary: Number of Participants With a Response for Cohorts 1 and 3 — 5; 10 Participants

Primary: Proportion of Patients Who Achieve a Confirmed Response — 0.0800; 0; 0 proportion of responders

Primary: Number of Participants With Complete Response of the Combination of Ibrutinib, Fludarabine, and Pembrolizumab in Patients With High-risk and/or Relapsed/Refractory…

Primary: Complete Response Rate — 10 percentage of participants

Primary: Overall Response Rate (ORR) Assessed by the Investigator — 83.5; 74.2 percentage of participants — p=<0.0001

Primary: To Establish the Overall Response Rate Measured at 24 Weeks After First Dose of Lenalidomide Using This Dosing Regimen — 0; 5; 28 participants

Primary: Number of Participants With an Overall Response — 23; 3; 26 Participants

Primary: PFS (Progression Free Survival) by Independent Review Committee (IRC), Limited to the Time of Primary Analysis 06 November 2013 — 8.1; NA months — p=<0.0001

Primary: Response Rate — 55.2 percentage

Primary: Overall Response Rate (ORR) — 64.8; 69.4 percentage of participants

Primary: Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to Adverse Events (AEs) — 3; 6…

Primary: Progression-free Survival (PFS) — NA; 8.38 months — p=<0.0001

Primary: Maximum-tolerated Dose of Dinaciclib When Given in Combination With Ofatumumab, Defined as a Dose Level Where at Most One of 6 Evaluable Patients Has a Dose Limiting…

Primary: Number of Participants With Complete Response (CR) — 14 participants

Primary: Overall Response Rate — 77.8 % of participants with response by PI

Primary: Complete Response (CR) — 12 Participants

Primary: Complete Response Rate — 36 percentage of patients

Primary: Recommended Phase 2 Dose of BI 836826 in Combination With Ibrutinib

Primary: Participants With a Response — 0; 3 Participants

Primary: Number of Participants With a Confirmed Response [Complete Response (CR) and Partial Response (PR)] on 2 Consecutive Evaluations at Least 4 Weeks Apart — 0 participants

Primary: Overall Participant Response Rate: Percentage of Participants With Complete + Partial Response According to Revised National Cancer Institute-sponsored Working Group…

Primary: Overall Response Rate — 6; 7 Participants

Primary: Overall Response (OR) Rate — 36 Participants